Advertisement

Topics

Latest "Ganaxolone Phase Data Supports Progressing Phase Patients With" News Stories

12:58 EDT 24th June 2018 | BioPortfolio

Here are the most relevant search results for "Ganaxolone Phase Data Supports Progressing Phase Patients With" found in our extensive news archives from over 250 global news sources.

More Information about Ganaxolone Phase Data Supports Progressing Phase Patients With on BioPortfolio

In addition to our news stories we have dozens of PubMed Articles about Ganaxolone Phase Data Supports Progressing Phase Patients With for you to read. Along with our medical data and news we also list Ganaxolone Phase Data Supports Progressing Phase Patients With Clinical Trials, which are updated daily. BioPortfolio also has a large database of Ganaxolone Phase Data Supports Progressing Phase Patients With Companies for you to search.

Showing "Ganaxolone Phase Data Supports Progressing Phase Patients With" News Articles 1–25 of 45,000+

Sunday 24th June 2018

Insulet Presents Positive Clinical Trial Results for the Omnipod® Horizon™ Hybrid Closed-Loop System at the American Diabetes Association's 78th Scientific Sessions

Omnipod® Horizon™ System Significantly Improves Glycemic Control in Patients with Type 1 Diabetes Insulet Corporation (NASDAQ:PODD) (Insulet or the Company), the leader in tubeless insulin pump technology with its Omnipod® Insulin Management System (Omnipod Sys


Human Insulin Could Be Front-Line for Many With Type 2 Diabetes

In patients with type 2 diabetes starting insulin therapy for the first time, there was no difference in glycemic control or severe hypoglycemia between those using NPH insulin or more expensive analogs. Medscape Medical News

Reflex Syncope: What You Need to Know

(MedPage Today) -- Patients faint at the sight of blood all the time


Poll: 66% Of Voters Oppose Trump DOJ's Move To Gut Patient Protections

Two-thirds of U.S. voters disapprove of the Trump Justice Department’s decision to support a lawsuit that would eliminate popular protections for patients with preexisting conditions under the Affordable Care Act.

Bilateral empathy lowers patient expectations

Generally speaking, patients and physicians are working towards good health. While many patient expectations can be unreasonable, others are practical; this article amalgamates them. Can you identify the absurd demands? But multiply half of the listed expectations by hundreds or thousands of patients, and we begin to understand why there is such a high rate […]

Saturday 23rd June 2018

Targeting the affective brain—a randomized controlled trial of real-time fMRI neurofeedback in patients with depression

Week in Review: CITIC Offers $3.6 Billion to Acquire China Biologic

Deals and Financings  CITIC Capital has submitted a $3.6 billion bid to acquire China Biologic Products, one of China's five largest plasma-based biopharmas; CSL Limited of Australia will pay $102 million to buy 20% of RuiDe Biological. a China plasma company; one year ago it paid $352 million for an 80% stake in RuiDe; Stealth Biotherapeutics, a Boston

Chinese team successfully simulate a 64-qubit circuit

The quantum computer is a device based on the principles of quantum mechanics. Comp

Eli Lilly: Lispro Shows Improved Blood Sugar Control In Phase 1b Studies

INDIANAPOLIS (dpa-AFX) - Eli Lilly and Company (LLY) announced its ultra rapid lispro (URLi) led to improved and sustained blood sugar control after meals in people with type 1 and type 2 diabetes...

180-Day Implantable CGM Deemed Safe in T1D Patients

(MedPage Today) -- The system's accuracy stabilized with longer use, researchers reported

CASI, Yiling Wanzhou International Pharma ink contract manufacturing pact for entecavir and cilostazol

CASI Pharmaceuticals, Inc, a biopharmaceutical company dedicated to the development and delivery of high quality, cost─effective pharmaceutical products and innovative therapeutics to patients in the US,

KnipBio Awarded SBIR Phase I Grant to Investigate Effect of Dietary Components on Fish Health

The post KnipBio Awarded SBIR Phase I Grant to Investigate Effect of Dietary Components on Fish Health appeared first on SynBioBeta.

Merck Reports New Data From Comparative Trials With Sitagliptin With JANUVIA

KENILWORTH (NJ) (dpa-AFX) - Merck (MRK) announced new data from the Comparative Trials with Sitagliptin (CompoSIT) clinical trials with JANUVIA (sitagliptin). The company said, in the CompoSIT-I s...

VIA Opens Newest Park Ride Facility in Stone Oak

It's designed and located to provide convenient, affordable transportation options for commuters along the U.S. 281 corridor. The next phase of the Stone Oak facility Read more...

Cost Issues Prevent a Quarter of Patients From Taking Insulin

A new study adds evidence to the ongoing insulin price controversy in the US, finding that 25% of patients with diabetes underuse insulin on cost grounds, which adversely affects their glycemic control. Medscape Medical News

Zealand Pharma presents two dasiglucagon milestone studies at the 78th Scientific Sessions of the American Diabetes Association (ADA)

Press Release - No. 17/2018 Zealand Pharma presents two dasiglucagon milestone studies at the 78th Scientific Sessions of the American Diabetes Association (ADA) Low doses of dasiglucagon effectively counteract low blood glucose in people with type 1 diabetes Long-term safety and tolerability of dasiglucagon confirmed Results support use of dasiglucagon in a dual-

Survey demonstrating underuse of glucagon rescue kits in type 1 diabetes patients to be presented at the ADA's 78th Scientific Sessions

Press Release - No. 16/2018 Survey demonstrating underuse of glucagon rescue kits in type 1 diabetes patients to be presented at the ADA's 78th Scientific Sessions T1D Exchange and Dr. Morey Haymond, MD, to present a Zealand Pharma supported survey of use of glucagon rescue kits by type 1 diabetes patients and caregivers Results demonstrate underuse of glucagon res...

Medtronic gets US FDA nod for use of MiniMed 670G system patients with type 1 diabetes seven years of age and older

Medtronic plc, the global leader in medical technology, announced that the US Food and Drug Administration (FDA) has approved the use of the MiniMed 670G system in patients with type 1 diabetes seven years of age

Eli Lilly: Trulicity Phase 2 Data Shows Efficacy In People With Type 2 Diabetes

INDIANAPOLIS (dpa-AFX) - Eli Lilly and Company (LLY) reported that two investigational doses of the companys's dulaglutide (4.5 mg and 3.0 mg), as well as Trulicity (dulaglutide) 1.5 mg, provided ...

Array BioPharma Reports Phase 3 BEACON CRC Data; 62% Observed Overall Survival

WASHINGTON (dpa-AFX) - Array BioPharma Inc. (ARRY) announced updated safety and efficacy results, including overall survival, from the safety lead-in of the Phase 3 BEACON CRC trial evaluating the...

Merck Presents New Data from the Comparative Trials with Sitagliptin (CompoSIT) Clinical Trial Program with JANUVIA® (sitagliptin)

Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced new data from the Comparative Trials with Sitagliptin (CompoSIT) clinical trials with JANUVIA® (sitagliptin). In the CompoSIT-I study, initiation of insulin therapy while continuing treatment with JANUVIA resulted in greater blood glucose reductions and more patients rea...

Dr. John R. Burroughs of Springs Aesthetics Now Offering vFit PLUS Feminine Wellness Treatment Device

vFit PLUS a proven and safe at-home feminine wellness device that improves vaginal health COLORADO SPRINGS, Colo. (PRWEB) June 23, 2018 Dr. John R. Burroughs, the Medical Director of Springs Aesthetics, is proud to be the first medical spa in Colorado Springs to offer vFit PLUS for sale. This revolutionary device promotes feminine and vaginal health in a safe and proven manner that clients can us...

Real-World Evidence Shows Oral INVOKANA® (canagliflozin) Results in Greater Weight Loss and ...

One of the two real-world studies, which was based on data from the HealthCore Integrated Research Database, showed that INVOKANA ®treatment resulted in similar Read more...

Malignant Glioma | A Pipeline Analysis Report 2018 | Technavio

Technavio has announced their latest pipeline analysis report on the malignant glioma market. The report includes a

Fabry Disease | A Pipeline Analysis Report 2018 | Technavio

Technavio has announced their latest pipeline analysis report on the Fabry disease market. The report includes a detaile


Advertisement
Quick Search
Advertisement
Advertisement

 

News Quicklinks